Citations

Clear

9383 citation(s) found for "Thomas, PS".

Distinguishing Ventricular Arrhythmia Originating from the Right Coronary Cusp, Peripulmonic Valve Area, and the Right Ventricular Outflow Tract: Utility of Lead I
Ebrille, Elisa , Chandra, Vishnu , Syed, Faisal F. , Muñoz, Freddy Del Carpio, Nanda, Sudip , Hai, Jo Jo , Cha, Yong‐Mei , Friedman, Paul A. , Hammill, Stephen C., Munger, Thomas M. , Venkatachalam, K, Packer, Douglas L. , Asirvatham, Samuel J. , Syed, Faisal, Del Carpio Munoz, Freddy, Munoz, Freddy Del‐Carpio , Asirvatham, Samuel J

Mayo Clinic

Journal of Cardiovascular Electrophysiology | November 25, 2013 | Volume: 25 | Issue: 4 | Pages: 404-410

10.1111/jce.12330 | PMID 24806530 Get It

ECG Lead I and Outflow Tract ArrhythmiaIntroductionOutflow tract ventricular arrhythmia (OTVA) can be complicated to target for ablation when originating from either the periaortic or pulmonary valve (PV) region. Both sites may present with a small R wave in lead V1. However, the utility of lead I in distinguishing these arrhythmia locations is unknown.Methods and ResultsThirty‐six consecutive patients (mean age 41 ± 14 years, 13 male) underwent catheter ablation for OTVA. OTVA origin was determined from intracardiac electrogram tracings and electroanatomic maps. Observers blinded to results measured QRS waveform amplitude and duration from standard 12‐lead ECG tracings. Measurements with highest diagnostic performance were modeled into an algorithm. Sites of successful ablation were anterior right ventricular outflow tract (RVOT; n = 6), posterior RVOT (n = 4), PV (n = 18), and right coronary cusp (RCC; n = 8). Highest performing surface ECG discriminators were from lead I to V1 vectors: RCC, lead I R wave ≥ 1.5 mV, and V1 R wave ≥2.0 mV (sensitivity 87%, specificity 93%); PV, V1 R wave > 0 mV, and lead I R/(R+S) ≤ 0.75 (sensitivity 78%, specificity 72%); anterior RVOT, V1 R wave = 0 mV, and lead I R/(R+S) <0.4 (sensitivity 67%, specificity 97%); posterior RVOT, V1 R wave > 0 mV, and lead I R/(R+S) > 0.75 (sensitivity 75%, specificity 84%). Sequential algorithmic application of these criteria resulted in an overall accuracy of 72% in predicting site of OTVA origin.ConclusionsA relatively large R wave in lead I is seen with RCC origin but not PV origin. A sequential algorithm has limited but potentially significant value beyond assessment of lead I in approaching OTVA.
Risk of Ovarian Cancer and the NF-κB Pathway: Genetic Association with IL1A and TNFSF10
Charbonneau, Bridget, Block, Matthew S., Bamlet, William R., Vierkant, Robert A., Kalli, Kimberly R., Fogarty, Zachary, Rider, David N., Sellers, Thomas A., Tworoger, Shelley S., Poole, Elizabeth, Risch, Harvey A., Salvesen, Helga B., Kiemeney, Lambertus A., Baglietto, Laura, Giles, Graham G., Severi, Gianluca, Trabert, Britton, Wentzensen, Nicolas, Chenevix-Trench, Georgia, group, for AOCS/ACS, Whittemore, Alice S., Sieh, Weiva, Chang-Claude, Jenny, Bandera, Elisa V., Orlow, Irene, Terry, Kathryn, Goodman, Marc T., Thompson, Pamela J., Cook, Linda S., Rossing, Mary Anne, Ness, Roberta B., Narod, Steven A., Kupryjanczyk, Jolanta, Lu, Karen, Butzow, Ralf, Dörk, Thilo, Pejovic, Tanja, Campbell, Ian, Le, Nhu D., Bunker, Clareann H., Bogdanova, Natalia, Runnebaum, Ingo B., Eccles, Diana, Paul, James, Wu, Anna H., Gayther, Simon A., Hogdall, Estrid, Heitz, Florian, Kaye, Stanley B., Karlan, Beth Y., Anton-Culver, Hoda, Gronwald, Jacek, Hogdall, Claus K., Lambrechts, Diether, Fasching, Peter A., Menon, Usha, Schildkraut, Joellen, Pearce, Celeste Leigh, Levine, Douglas A., Kjaer, Susanne Kruger, Cramer, Daniel, Flanagan, James M., Phelan, Catherine M., Brown, Robert, Massuger, Leon F.A.G., Song, Honglin, Doherty, Jennifer A., Krakstad, Camilla, Liang, Dong, Odunsi, Kunle, Berchuck, Andrew, Jensen, Allan, Lubiński, Jan, Nevanlinna, Heli, Bean, Yukie T., Lurie, Galina, Ziogas, Argyrios, Walsh, Christine, Despierre, Evelyn, Brinton, Louise, Hein, Alexander, Rudolph, Anja, Dansonka-Mieszkowska, Agnieszka, Olson, Sara H., Harter, Philipp, Tyrer, Jonathan, Vitonis, Allison F., Brooks-Wilson, Angela, Aben, Katja K., Pike, Malcolm C., Ramus, Susan J., Wik, Elisabeth, Cybulski, Cezary, Lin, Jie, Sucheston, Lara, Edwards, Robert, McGuire, Valerie, Lester, Jenny, Bois, Andreas du, Lundvall, Lene, Wang-Gohrke, Shan, Szafron, Lukasz M., Lambrechts, Sandrina, Yang, Hannah, Beckmann, Matthias W., Pelttari, Liisa M., Altena, Anne M. Van, Berg, David van den, Halle, Mari K., Gentry-Maharaj, Aleksandra, Schwaab, Ira, Chandran, Urmila, Menkiszak, Janusz, Ekici, Arif B., Wilkens, Lynne R., Leminen, Arto, Modugno, Francesmary, Friel, Grace, Rothstein, Joseph H., Vergote, Ignace, Garcia-Closas, Montserrat, Hildebrandt, Michelle A.T., Sobiczewski, Piotr, Kelemen, Linda E., Pharoah, Paul D.P., Moysich, Kirsten, Knutson, Keith L., Cunningham, Julie M., Fridley, Brooke L., Goode, Ellen L., Vierkant, Robert A. , Bamlet, William R. , Lu, Karen H. , Ramus, Susan J. , Kjær, Susanne K. , Høgdall, Estrid , Høgdall, Claus , Goodman, Marc T. , García‐Closas, Montserrat , Chenevix‐Trench, Georgia , Lubiński, Jan , Nevanlinna, Heli , Olson, Sara H. , Dörk, Thilo , Giles, Graham G. , Severi, Gianluca , Menon, Usha , Terry, Kathryn L. , Tworoger, Shelley S. , Baglietto, Laura , Bogdanova, Natalia , Ekici, Arif B. , Orlow, Irene , Eccles, Diana , Hein, Alexander , Lambrechts, Diether , Jensen, Allan , Brown, Robert , Bandera, Elisa V. , Campbell, Ian , Kiemeney, Lambertus A. , Aben, Katja K.H. , Sieh, Weiva , Fogarty, Zachary C. , Levine, Douglas A. , Kupryjańczyk, Jolanta , Heitz, Florian , Flanagan, James M. , Dansonka‐Mieszkowska, Agnieszka , Menkiszak, Janusz , Pelttari, Liisa M. , Krakstad, Camilla , Trabert, Britton , Sobiczewski, Piotr , Lambrechts, Diether , Szafron, Lukasz M. , Charbonneau, Bridget, Block, Matthew S., Bamlet, William R., Vierkant, Robert A., Kalli, Kimberly R., Fogarty, Zachary, Rider, David N., Sellers, Thomas A., Tworoger, Shelley S., Poole, Elizabeth, Risch, Harvey A., Salvesen, Helga B., Kiemeney, Lambertus A., Baglietto, Laura, Giles, Graham G., Severi, Gianluca, Trabert, Britton, Wentzensen, Nicolas, Chenevix-Trench, Georgia, group, for AOCS/ACS, Whittemore, Alice S., Sieh, Weiva, Chang-Claude, Jenny, Bandera, Elisa V., Orlow, Irene, Terry, Kathryn, Goodman, Marc T., Thompson, Pamela J., Cook, Linda S., Rossing, Mary Anne, Ness, Roberta B., Narod, Steven A., Kupryjanczyk, Jolanta, Lu, Karen, Butzow, Ralf, Dörk, Thilo, Pejovic, Tanja, Campbell, Ian, Le, Nhu D., Bunker, Clareann H., Bogdanova, Natalia, Runnebaum, Ingo B., Eccles, Diana, Paul, James, Wu, Anna H., Gayther, Simon A., Hogdall, Estrid, Heitz, Florian, Kaye, Stanley B., Karlan, Beth Y., Anton-Culver, Hoda, Gronwald, Jacek, Hogdall, Claus K., Lambrechts, Diether, Fasching, Peter A., Menon, Usha, Schildkraut, Joellen, Pearce, Celeste Leigh, Levine, Douglas A., Kjaer, Susanne Kruger, Cramer, Daniel, Flanagan, James M., Phelan, Catherine M., Brown, Robert, Massuger, Leon F.A.G., Song, Honglin, Doherty, Jennifer A., Krakstad, Camilla, Liang, Dong, Odunsi, Kunle, Berchuck, Andrew, Jensen, Allan, Lubiński, Jan, Nevanlinna, Heli, Bean, Yukie T., Lurie, Galina, Ziogas, Argyrios, Walsh, Christine, Despierre, Evelyn, Brinton, Louise, Hein, Alexander, Rudolph, Anja, Dansonka-Mieszkowska, Agnieszka, Olson, Sara H., Harter, Philipp, Tyrer, Jonathan, Vitonis, Allison F., Brooks-Wilson, Angela, Aben, Katja K., Pike, Malcolm C., Ramus, Susan J., Wik, Elisabeth, Cybulski, Cezary, Lin, Jie, Sucheston, Lara, Edwards, Robert, McGuire, Valerie, Lester, Jenny, Bois, Andreas du, Lundvall, Lene, Wang-Gohrke, Shan, Szafron, Lukasz M., Lambrechts, Sandrina, Yang, Hannah, Beckmann, Matthias W., Pelttari, Liisa M., Altena, Anne M. Van, Berg, David van den, Halle, Mari K., Gentry-Maharaj, Aleksandra, Schwaab, Ira, Chandran, Urmila, Menkiszak, Janusz, Ekici, Arif B., Wilkens, Lynne R., Leminen, Arto, Modugno, Francesmary, Friel, Grace, Rothstein, Joseph H., Vergote, Ignace, Garcia-Closas, Montserrat, Hildebrandt, Michelle A.T., Sobiczewski, Piotr, Kelemen, Linda E., Pharoah, Paul D.P., Moysich, Kirsten, Knutson, Keith L., Cunningham, Julie M., Fridley, Brooke L., Goode, Ellen L., Trabert, B , Pelttari, L M , Nevanlinna, H , Dörk, Thilo , Lambrechts, Diether , Giles, Graham G , Kiemeney, Lambertus A , Kjaer, Susanne K , Ramus, Susan J , Tworoger, Shelley S , Hein, Alexander , Jensen, Allan , Vierkant, Robert A , Eccles, Diana , Menon, Usha , Szafron, Lukasz M , Moysich, Kirsten , Orlow, Irene , Campbell, Ian G , Bamlet, William R , Menkiszak, Janusz , Brown, Robert , Fogarty, Zachary C , Flanagan, James M , Heitz, Florian , Kupryjanczyk, Jolanta , Lambrechts, Diether , Sieh, Weiva , García-Closas, Montserrat , Severi, Gianluca , Ekici, Arif B , Bogdanova, Natalia V , Chenevix-Trench, Georgia , Høgdall, Estrid , Høgdall, Claus K , Lubinski, Jan , Baglietto, Laura , Goodman, Marc T , Bandera, Elisa V.

Mayo Clinic

Cancer Research | November 22, 2013 | Volume: 74 | Issue: 3 | Pages: 852-861

10.1158/0008-5472.can-13-1051 | PMID 24272484 Get It

Abstract A missense single-nucleotide polymorphism (SNP) in the immune modulatory gene IL1A has been associated with ovarian cancer risk (rs17561). Although the exact mechanism through which this SNP alters risk of ovarian cancer is not clearly understood, rs17561 has also been associated with risk of endometriosis, an epidemiologic risk factor for ovarian cancer. Interleukin-1α (IL1A) is both regulated by and able to activate NF-κB, a transcription factor family that induces transcription of many proinflammatory genes and may be an important mediator in carcinogenesis. We therefore tagged SNPs in more than 200 genes in the NF-κB pathway for a total of 2,282 SNPs (including rs17561) for genotype analysis of 15,604 cases of ovarian cancer in patients of European descent, including 6,179 of high-grade serous (HGS), 2,100 endometrioid, 1,591 mucinous, 1,034 clear cell, and 1,016 low-grade serous, including 23,235 control cases spanning 40 studies in the Ovarian Cancer Association Consortium. In this large population, we confirmed the association between rs17561 and clear cell ovarian cancer [OR, 0.84; 95% confidence interval (CI), 0.76–0.93; P = 0.00075], which remained intact even after excluding participants in the prior study (OR, 0.85; 95% CI, 0.75–0.95; P = 0.006). Considering a multiple-testing–corrected significance threshold of P &lt; 2.5 × 10−5, only one other variant, the TNFSF10 SNP rs6785617, was associated significantly with a risk of ovarian cancer (low malignant potential tumors OR, 0.85; 95% CI, 0.79–0.91; P = 0.00002). Our results extend the evidence that borderline tumors may have a distinct genetic etiology. Further investigation of how these SNPs might modify ovarian cancer associations with other inflammation-related risk factors is warranted. Cancer Res; 74(3); 852–61. ©2013 AACR.
Cardiac rehabilitation is associated with reduced long-term mortality in patients undergoing combined heart valve and CABG surgery
Pack, Quinn R. , Lahr, Brian D. , Greason, Kevin L. , Squires, Ray W. , Zhang, Zixin , Thomas, Randal J. , Lahr, Brian, Goel, Kashish , López-Jiménez, Francisco , Thomas, Randal

Mayo Clinic

European Journal of Preventive Cardiology | November 22, 2013 | Volume: 22 | Issue: 2 | Pages: 159-168

10.1177/2047487313512219 | PMID 24265289 Get It

Importance of Achieving Stringent Complete Response After Autologous Stem-Cell Transplantation in Multiple Myeloma
Kapoor, Prashant , Kumar, Shaji , Dispenzieri, Angela , Lacy, Martha Q. , Dingli, David , Russell, Stephen J. , Hayman, Suzanne R. , Lust, John A., Leung, Nelson , Lin, Yi , Zeldenrust, Steven R., McCurdy, Arleigh , Greipp, Philip R., Kyle, Robert A. , Buadi, Francis K. , Witzig, Thomas E. , Rajkumar, S. Vincent , Gertz, Morie A. , Leung, Nelson , Dispenzieri, Angela , Russell, Stephen J , Dingli, David , Lin, Yi , McCurdy, Arleigh

Mayo Clinic

Journal of Clinical Oncology | November 18, 2013 | Volume: 31 | Issue: 36 | Pages: 4529-4535

10.1200/jco.2013.49.0086 | PMID 24248686 Get It

Purpose To study the impact of achieving stringent complete response (sCR), an increasingly attainable goal, after autologous stem-cell transplantation (ASCT) in patients with multiple myeloma (MM). Patients and Methods Maximal response rates were determined in 445 consecutive patients who underwent ASCT within 12 months of diagnosis of MM. The patients achieving varying degrees of complete response (CR) are the focus of our study. Results One hundred and nine patients (25%) achieved sCR after ASCT. The median overall survival (OS) rate from the time of transplantation for patients attaining sCR was not reached (NR), in contrast to those patients achieving conventional complete response (CR; n = 37; OS, 81 months) or near CR (nCR; n = 91; OS, 60 months; P < .001). Five-year OS rates were 80%, 53%, and 47% for sCR, CR, and nCR, respectively. The median time to progression (TTP) from ASCT of patients achieving sCR was significantly longer (50 months) than TTP of patients achieving CR or nCR (20 months and 19 months, respectively). On multivariable analysis, post-ASCT response of sCR was an independent prognostic factor for survival (hazard ratio, 0.44; 95% CI, 0.25 to 0.80; versus CR; P = .008), in addition to proliferation rate, pre-ASCT cytogenetics, and performance status. OS rates of patients attaining sCR continued to remain superior at 2-year landmark (median, NR v 70 months for conventional CR group; P = .007). Conclusion Improved long-term outcome is seen after ASCT with achievement of sCR when compared with lesser degrees of responses. Myeloma trials reporting the response rates should identify patients achieving sCR and CR separately, owing to markedly disparate outcomes of the two categories.
A “Teapot” Atrial Septal Aneurysm with Spontaneous Thrombus in an Asymptomatic Patient
Aryal, Madan Raj , Pradhan, Rajesh , Pandit, Aashrayata Aryal, Polinsky, Ronald J.

Mayo Clinic

Circulation | November 18, 2013 | Volume: 128 | Issue: 21 | Pages: No page available

10.1161/circulationaha.113.004674 | PMID 24249622 Get It

A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46 450 cases and 42 461 controls from the breast cancer association consortium
Herránz, Jesús , Michailidou, Kyriaki , Zamora, M. Pilar , Pérez, José Ignacio Arias , González‐Neira, Anna , Pita, Guillermo , Alonso, M. Rosario, Wang, Qin , Bolla, Manjeet K. , Czene, Kamila , Eriksson, Mikael , Humphreys, Keith , Darabi, Hatef, Li, Jingmei , Hopper, John L. , Apicella, Carmel, Southey, Melissa C. , Chenevix‐Trench, Georgia , Investigators, kConFab, Group, Australian Ovarian Cancer Study, Swerdlow, Anthony J. , Ashworth, Alan , Orr, Nicholas, Schoemaker, Minouk J. , Jakubowska, Anna , Lubiński, Jan , Jaworska–Bieniek, Katarzyna, Durda, Katarzyna, Andrulis, Irene L. , Knight, Julia A. , Glendon, Gord, Mulligan, Anna Marie , Bojesen, Stig E. , Nordestgaard, Børge G. , Flyger, Henrik, Nevanlinna, Heli , Muranen, Taru , Aittomäki, Kristiina, Blomqvist, Carl , Chang‐Claude, Jenny , Flesch‐Janys, Dieter, Vachon, Celine M. , Purrington, Kristen S. , Winqvist, Robert , Pylkäs, Katri , Jukkola‐Vuorinen, Arja , Grip, Mervi, Dunning, Alison M. , Shah, Mitul , Guénel, Pascal , Truong, Thérèse , Sanchez, Marie, Mulot, Claire , Brenner, Hermann , Dieffenbach, Aida Karina, Stegmaier, Christa, Lindblom, Annika , Margolin, Sara , Hooning, Maartje J. , Hollestelle, Antoinette , Collée, J. Margriet, Jager, Agnes , Cox, Angela , Brock, Ian W., Reed, Malcolm , Devilee, Peter , Tollenaar, Robert A.E.M., Seynaeve, Caroline, Haiman, Christopher A., Henderson, Brian E., Schumacher, Fredrick R. , Simard, Jacques , Dumont, Martine , Soucy, Penny, Dörk, Thilo , Bogdanova, Natalia , Hamann, Ute , Rüdiger, Thomas , Ulmer, Hans-Ulrich, Fasching, Peter A. , Häberle, Lothar , Ekici, Arif B. , Beckmann, Matthias W. , Fletcher, Olivia , Johnson, Nichola , dos‐Santos‐Silva, Isabel , Peto, Julian, Radice, Paolo , Peterlongo, Paolo , Peissel, Bernard , Mariani, P., Severi, Gianluca , Baglietto, Laura , Sawyer, Elinor J. , Tomlinson, Ian , Kerin, Michael J. , Miller, Nicola, Marmé, F., Burwinkel, Barbara , Mannermaa, Arto, Kataja, Vesa , Kosma, Veli‐Matti , Hartikainen, Jaana M. , Lambrechts, Diether , Yesilyurt, Betül T., Floris, Giuseppe , Leunen, Karin, Alnæs, Grethe Grenaker, Kristensen, Vessela N. , Børresen‐Dale, Anne‐Lise , García‐Closas, Montserrat , Lissowska, Jolanta , Figueroa, Jonine D. , Schmidt, Marjanka K. , Verhoef, Senno, Rutgers, Emiel J. , Brauch, Hiltrud , Brüning, Thomas , Ko, Yon‐Dschun, Network, The GENICA, TNBCC, The, Yannoukakos, Drakoulis , Malats, Núria , Easton, Douglas F. , Manoukian, Siranoush , Durocher, Francine , Zaffaroni, Daniela , Orr, Nick , Thorne, Heather , Bowtell, David D.L. , Rabstein, Sylvia , Lotz, Anne , Lambrechts, Diether , Milne, Roger L. , Dennis, Joe , Tyrer, Jonathan P. , Eriksson, Mikael , Anton‐Culver, Hoda , Neuhausen, Susan L. , Ziogas, Argyrios , Clarke, Christina A. , Dite, Gillian S. , Investigators, kConFab, Group, Australian Ovarian Cancer Study, Orr, Nicholas, Rudolph, Anja , Seibold, Petra , Wang, Xianshu , Olson, Janet E. , Vachon, Celine M. , Sanchez, Marie, Arndt, Volker , Hooning, Maartje J. , Marchand, Loı̈c Le , Försti, Asta , Giles, Graham G. , Mannermaa, Arto, Chanock, Stephen Jacob , Broeks, Annegien , Network, The GENICA, Couch, Fergus J. , Toland, Amanda Ewart , TNBCC, The, Pharoah, Paul D.P. , Hall, Per N , Benı́tez, Javier , Nevanlinna, H , Dörk, Thilo , Lambrechts, Diether , Peterlongo, Paolo , Swerdlow, Anthony J , Radice, Paolo , Lissowska, Jolanta , Southey, Melissa C , Malats, Nuria , Dunning, Alison M , Jakubowska, Anna , Lambrechts, Diether , Brenner, Hermann , Cox, Angela , Guénel, Pascal , Li, Jingmei , Muranen, Taru A , García-Closas, Montserrat , Schmidt, Marjanka K , Severi, Gianluca , Ekici, Arif B , Michailidou, Kyriaki , Hartikainen, Jaana M , Bogdanova, Natalia V , Simard, Jacques , Chenevix-Trench, Georgia , Figueroa, Jonine D , Czene, Kamila , Bowtell, David D , Pylkäs, Katri , Yannoukakos, Drakoulis , Devilee, Peter , Manoukian, Siranoush , Lubinski, Jan , Baglietto, Laura , Fletcher, Olivia , Bojesen, Stig E , Purrington, Kristen S , Schoemaker, Minouk J , Truong, Therese , Brauch, Hiltrud , Lindblom, Annika , Sawyer, Elinor J , Orr, Nick

Mayo Clinic

Human Molecular Genetics | November 16, 2013 | Volume: 23 | Issue: 7 | Pages: 1934-1946

10.1093/hmg/ddt581 | PMID 24242184 Get It

Abstract Part of the substantial unexplained familial aggregation of breast cancer may be due to interactions between common variants, but few studies have had adequate statistical power to detect interactions of realistic magnitude. We aimed to assess all two-way interactions in breast cancer susceptibility between 70 917 single nucleotide polymorphisms (SNPs) selected primarily based on prior evidence of a marginal effect. Thirty-eight international studies contributed data for 46 450 breast cancer cases and 42 461 controls of European origin as part of a multi-consortium project (COGS). First, SNPs were preselected based on evidence (P &lt; 0.01) of a per-allele main effect, and all two-way combinations of those were evaluated by a per-allele (1 d.f.) test for interaction using logistic regression. Second, all 2.5 billion possible two-SNP combinations were evaluated using Boolean operation-based screening and testing, and SNP pairs with the strongest evidence of interaction (P &lt; 10−4) were selected for more careful assessment by logistic regression. Under the first approach, 3277 SNPs were preselected, but an evaluation of all possible two-SNP combinations (1 d.f.) identified no interactions at P &lt; 10−8. Results from the second analytic approach were consistent with those from the first (P &gt; 10−10). In summary, we observed little evidence of two-way SNP interactions in breast cancer susceptibility, despite the large number of SNPs with potential marginal effects considered and the very large sample size. This finding may have important implications for risk prediction, simplifying the modelling required. Further comprehensive, large-scale genome-wide interaction studies may identify novel interacting loci if the inherent logistic and computational challenges can be overcome.
Efficient B Cell Responses to Borrelia hermsii Infection Depend on BAFF and BAFFR but Not TACI
Dickinson, Gregory S., Sun, Guizhi, Bram, Richard J. , Alugupalli, Kishore R.

Mayo Clinic

Infection and Immunity | November 12, 2013 | Volume: 82 | Issue: 1 | Pages: 453-459

10.1128/iai.01147-13 | PMID 24218480 Get It

ABSTRACT T cell-independent antibody responses develop rapidly, within 3 to 4 days, and are critical for preventing blood-borne pathogens from evolving into life-threatening infections. The interaction of BAFF, also known as BLyS, with its receptors BAFFR and TACI on B cells is critical for B cell homeostasis and function. Using a synthetic polysaccharide antigen, it has previously been shown that TACI is critical for T cell-independent antibody responses. To examine the role of BAFFR and TACI in T cell-independent antibody responses to an active infection, we utilized the Borrelia hermsii infection system. In this infection system, T cell-independent responses mediated by the B1b cell subset are critical for controlling bacteremia. We found that B1b cells express BAFFR and TACI and that the surface expression of both receptors is upregulated on B1b cells following exposure to whole B. hermsii cells. Surprisingly, we found that TACI −/− mice are not impaired either in specific antibody responses to B. hermsii or in controlling B. hermsii bacteremia. In contrast, TACI-deficient mice immunized with heat-killed type 3 serotype pneumococcus cells are impaired in generating pneumococcal polysaccharide-specific responses and succumb to challenge with live type 3 serotype pneumococcus, indicating that TACI is required for T cell-independent antibody responses to bacterial-associated polysaccharides. Although we have found that TACI is dispensable for controlling B. hermsii infection, mice deficient in BAFFR or BAFF exhibit impairment in B. hermsii -specific IgM responses and clearance of bacteremia. Collectively, these data indicate a disparity in the roles for TACI and BAFFR in primary T cell-independent antibody responses to bacterial pathogens.
Comparison of mRNA Splicing Assay Protocols across Multiple Laboratories: Recommendations for Best Practice in Standardized Clinical Testing
Whiley, Phillip J , Hoya, Miguel de la , Thomassen, Mads , Becker, Alexandra, Pedersen, Inge Søkilde , Montagna, Marco , Menéndez, Mireia , Quiles, Francisco, Gutiérrez‐Enríquez, Sara , Leeneer, Kim De , Tenés, Anna, Montalban, Gemma , Tserpelis, Demis, Yoshimatsu, Toshio F. , Tirapo, Carole, Raponi, Michela , Caldés, Trinidad , Blanco, Ana , Guidugli, Lucia, Garibay, Gorka Ruíz de , Wong, Ming, Tancredi, Mariella, Fachal, Laura , Ding, Yuan Chun , Kruse, Torben A., Lattimore, Vanessa , Kwong, Ava , Chan, Tsun Leung , Colombo, Mara , Vecchi, Giovanni De, Caligo, Maria A. , Baralle, Diana , Lázaro, Conxi , Radice, Paolo , Southey, Melissa C. , Houdayer, Claude , Fackenthal, Jim, Hansen, Thomas van Overeem , Vega, Ana , Dı́ez, Orland , Blok, Rien, Claes, Kathleen , Wappenschmidt, Barbara , Walker, Logan C. , Spurdle, Amanda B. , Brown, Melissa A. , Brandão, Rita D. , Santamariña, Marta , Couch, Fergus J. , Neuhausen, Susan L. , Caligo, Maria A , Spurdle, Amanda B , Vega, Ana , de la Hoya, Miguel , Diez, Orland , Gutiérrez-Enríquez, Sara , Radice, Paolo , Claes, Kathleen B M , Southey, Melissa C , Lazaro, Conxi , Montagna, Marco , Ruiz de Garibay, Gorka , Montalban, Gemma , De Leeneer, Kim , Hansen, Thomas van Overeem , Kwong, Ava , Fachal, Laura

Mayo Clinic

Clinical Chemistry | November 8, 2013 | Volume: 60 | Issue: 2 | Pages: 341-352

10.1373/clinchem.2013.210658 | PMID 24212087 Get It

Abstract BACKGROUND Accurate evaluation of unclassified sequence variants in cancer predisposition genes is essential for clinical management and depends on a multifactorial analysis of clinical, genetic, pathologic, and bioinformatic variables and assays of transcript length and abundance. The integrity of assay data in turn relies on appropriate assay design, interpretation, and reporting. METHODS We conducted a multicenter investigation to compare mRNA splicing assay protocols used by members of the ENIGMA (Evidence-Based Network for the Interpretation of Germline Mutant Alleles) consortium. We compared similarities and differences in results derived from analysis of a panel of breast cancer 1, early onset (BRCA1) and breast cancer 2, early onset (BRCA2) gene variants known to alter splicing (BRCA1: c.135-1G&gt;T, c.591C&gt;T, c.594-2A&gt;C, c.671-2A&gt;G, and c.5467+5G&gt;C and BRCA2: c.426-12_8delGTTTT, c.7988A&gt;T, c.8632+1G&gt;A, and c.9501+3A&gt;T). Differences in protocols were then assessed to determine which elements were critical in reliable assay design. RESULTS PCR primer design strategies, PCR conditions, and product detection methods, combined with a prior knowledge of expected alternative transcripts, were the key factors for accurate splicing assay results. For example, because of the position of primers and PCR extension times, several isoforms associated with BRCA1, c.594-2A&gt;C and c.671-2A&gt;G, were not detected by many sites. Variation was most evident for the detection of low-abundance transcripts (e.g., BRCA2 c.8632+1G&gt;A Δ19,20 and BRCA1 c.135-1G&gt;T Δ5q and Δ3). Detection of low-abundance transcripts was sometimes addressed by using more analytically sensitive detection methods (e.g., BRCA2 c.426-12_8delGTTTT ins18bp). CONCLUSIONS We provide recommendations for best practice and raise key issues to consider when designing mRNA assays for evaluation of unclassified sequence variants.
Functional Assays for Analysis of Variants of Uncertain Significance inBRCA2
Guidugli, Lucia, Carreira, Aura , Caputo, Sandrine M. , Ehlén, Åsa , Galli, Alvaro , Monteiro, Álvaro N.A. , Hansen, Thomas van Overeem , Neuhausen, Susan L. , Couch, Fergus J. , Vreeswijk, Maaike P.G. , Monteiro, Alvaro N , Hansen, Thomas van Overeem

Mayo Clinic

Human Mutation | November 6, 2013 | Volume: 35 | Issue: 2 | Pages: 151-164

10.1002/humu.22478 | PMID 24323938 Get It

Pneumatic Compression for Embolic Protection During Upper Extremity Endovascular Intervention
Cassar, Andrew, Barsness, Gregory W. , Wysokiński, Waldemar E. , Gifford, Shaun M., Bower, Thomas C., Edwards, William D. , Gulati, Rajiv , Wysokinski, Waldemar

Mayo Clinic

Vascular and Endovascular Surgery | November 1, 2013 | Volume: 48 | Issue: 1 | Pages: 70-73

10.1177/1538574413510622 | PMID 24178727 Get It

Embolic protection devices are occasionally employed during endovascular interventions to prevent complications caused by embolic debris. However, these devices have imperfect efficacy, confer risk of endovascular trauma, and are expensive. We report a patient with giant cell arteritis and symptomatic axillary artery stenosis, with a perceived elevated risk of distal embolization during endovascular intervention. We describe a straightforward embolic protection technique of brachial pressure cuff inflation during endovascular intervention and aspiration of displaced thrombotic material from the static column of blood. This novel, effective, and cost-free technique could also be employed in other vascular beds during endovascular intervention.